Observed Signal · Sep 25, 2026 · Corporate Update · Source: Johnson & Johnson
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Johnson & Johnson announced on September 25, 2026, that TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in a landmark axial psoriatic arthritis (PsA) study. Topline results met the primary and major secondary endpoints, including MRI-confirmed inflammation reduction. This is the first study to use objective MRI assessments to confirm axial involvement and demonstrate its reduction in PsA.
This announcement positions TREMFYA as the first IL-23 inhibitor with proven efficacy on axial symptoms in psoriatic arthritis, a historically difficult-to-treat manifestation. It strengthens Johnson & Johnson's immunology franchise and may shift competitive dynamics among IL-23 inhibitors.
MARKET SIGNALS
Track Johnson & Johnson Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Key Takeaways & Evidence Grounding
- On September 25, 2026, Johnson & Johnson announced topline results from a landmark axial psoriatic arthritis (PsA) study.
- TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in axial PsA.
- The study met its primary and major secondary endpoints, including significant improvement in MRI-confirmed inflammation.
- This is the first-ever study to use objective MRI assessments to confirm the presence of axial involvement and demonstrate axial inflammation reduction in PsA.
Connected Companies & Entities
“Johnson & Johnson is the pharmaceutical company that announced the clinical trial results for its drug TREMFYA (guselkumab).”
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
Isomorphic Labs seeks $5B round at $50B valuation
Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.
Johnson & Johnson Furnishes Q3 2026 Earnings Announcement via Current Report
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
WATCHLIST & BRIEFINGS
Receive future signals for Johnson & Johnson & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor Johnson & Johnson
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
